Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Thyroid Cancer, Papillary × Mitoxantrone × 1 year × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Endocrine 1

Conditions

Leukemia, Myeloid, Acute 19 Precursor Cell Lymphoblastic Leukemia-Lymphoma 6 Myelodysplastic Syndromes 4 Sarcoma, Myeloid 2 Leukemia, Biphenotypic, Acute 2 Leukemia 2 Thyroid Cancer, Papillary 1 Recurrence 1 Prostatic Neoplasms 1 Philadelphia Chromosome 1 Myeloproliferative Disorders 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Monocytic, Acute 1 Down Syndrome 1

Interventions

Vemurafenib 4 selpercatinib 3 Magnetic Resonance Spectroscopy 3 trametinib 2 entrectinib 2 dabrafenib 2 cobimetinib 2 X-Rays 2 Specimen Handling 2 tremelimumab 1 tovorafenib 1 spartalizumab 1 pralsetinib 1 pembrolizumab 1 lenvatinib 1 gallium Ga 68 dotatate 1 durvalumab 1 copanlisib 1 cabozantinib 1 Whole Body Imaging 1 Thyrotropin Alfa 1 Surveys and Questionnaires 1 Sunitinib 1 Robotic Surgical Procedures 1 Radiofrequency Ablation 1 Postoperative Period 1 Pharmacogenomic Testing 1 Phantoms, Imaging 1 Mitoxantrone 1 Iodine-131 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07354698 2026-01-21

MHI

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Phase 4 Not yet recruiting

EndocrineHead & Neck

Thyroid Cancer, Papillary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡